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Abstract
Aspartylglucosaminuria (AGU, McKusick 208400) is an autosomal recessive lysosomal storage disease caused by defective
degradation of Asn-linked glycoproteins. AGU mutations occur in the gene (AGA) for glycosylasparaginase, the enzyme
necessary for hydrolysis of the protein^oligosaccharide linkage in Asn-linked glycoprotein substrates undergoing metabolic
turnover. Loss of glycosylasparaginase activity leads to accumulation of the linkage unit Asn^GlcNAc in tissue lysosomes.
Storage of this fragment affects the pathophysiology of neuronal cells most severely. The patients notably suffer from
decreased cognitive abilities, skeletal abnormalities and facial grotesqueness. The progress of the disease is slower than in
many other lysosomal storage diseases. The patients appear normal during infancy and generally live from 25 to 45 years. A
specific AGU mutation is concentrated in the Finnish population with over 200 patients. The carrier frequency in Finland
has been estimated to be in the range of 2.5^3% of the population. So far there are 20 other rare family AGU alleles that have
been characterized at the molecular level in the world’s population. Recently, two knockout mouse models for AGU have
been developed. In addition, the crystal structure of human leukocyte glycosylasparaginase has been determined and the
protein has a unique KLLK sandwich fold shared by a newly recognized family of important enzymes called N-terminal
nucleophile (Ntn) hydrolases. The nascent single-chain precursor of glycosylase araginase self-cleaves into its mature K- and
L-subunits, a reaction required to activate the enzyme. This interesting biochemical feature is also shared by most of the Ntn-
hydrolase family of proteins. Many of the disease-causing mutations prevent proper folding and subsequent activation of the
glycosylasparaginase. ß 1999 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In 1967, Mahadavan and Tappel [1] puri¢ed and
characterized rat liver glycosylasparaginase (EC
3.5.1.26) which is the enzyme responsible for hydrol-
ysis of the glycosylamide bond that joins carbohy-
drate chains to Asn-linked glycoproteins. They deter-
mined the enzyme is an amidase that functions in the
lysosomes. In the very same year that the rat enzyme
was described, Jenner and Pollitt [3] published a
short proceedings report that large quantities of
Asn^GlcNAc, the linkage unit of Asn-linked glyco-
proteins, occurred in the urine of two mentally re-
tarded siblings in England. They then noted that the
activity of glycosylasparaginase was absent from the
tissues of the two patients [4]. This de¢ciency of the
enzyme suggested that they su¡ered from an inborn
error of metabolism which they named ‘aspartylgly-
cosaminuria’. During this same period while working
on his Ph.D. thesis in Finland, Jorma Palo observed
among a very large number of retarded persons
being clinically screened in his country that nine of
them excreted an unknown peptide material in their
urine [5]. Based on the Jenner and Pollitt publica-
tions the unknown compound was identi¢ed to be
Asn^GlcNAc [6]. Palo coined the term ‘AGU’ for
the disease (probably derived from PKU already
being a popularized term for phenylketonuria), and
soon it became evident that an AGU gene defect had
accumulated in the Finnish population [7].
Aspartylglucosaminuria (AGU, McKusick
208400), although rare outside of the Finnish popu-
lation, is the most common lysosomal storage disor-
der that directly involves glycoprotein catabolism.
There are over 200 patients in Finland, and approx-
imately one new case in 18 500 live births occurs
there [8]. The clinical hallmarks of the disease are:
slowly developing, progressive psychomotor retarda-
tion; facial grotesqueness; and skeletal and connec-
tive tissue abnormalities [9,10]. AGU children appear
normal for several years, but as juveniles and
throughout adolescence the major traits of mental
retardation and facial coarseness progressively wor-
sen. Thus, to a certain extent, AGU behaves as a
juvenile, or even adult, form of lysosomal storage
disease in which the pathology is not immediately
apparent at birth or during infancy [11]. Some com-
mon diagnostic changes in the young patients are
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aggressive behavior and delayed and diminished
communication skills. AGU patients can have rela-
tively long lives compared to patients with other
forms of lysosomal storage diseases, surviving up to
45^50 years [12,68]. As in all types of lysosomal stor-
age diseases, AGU tissues are characterized by en-
larged lysosomes. The principal storage material as
originally determined by Jenner and Pollitt [3] is
Asn^GlcNAc, but small amounts of other glycoas-
paragines with unexplained saccharide structures are
also sometimes noted [13,14,75]. Recently the crystal
structure of the human leukocyte enzyme was ob-
tained by Oinonen et al. [2], and the mechanism of
the reaction determined. This review will therefore
focus on our current knowledge about the biochem-
istry and structural biology of glycosylasparaginase
and discuss how this information can now explain
the manner by which speci¢c AGU mutations e¡ect
the disease. A recent book [87] and other important
reviews covering various aspects of AGU and glyco-
sylasparaginase have been published [68,69,79,88^
92].
2. Lysosomal degradation of ASN-linked
glycoproteins: general features
Degradation of Asn-linked glycoproteins com-
pletely to amino acids and sugars occurs in lyso-
somes in a two-part pathway (Fig. 1) [15]: (1) se-
quential release of non-reducing-end sugars by
exoglycosidases that accounts for the bulk of carbo-
hydrate removal; and (2) digestion of the protein and
protein-to-carbohydrate linkage region. Serum K1-
acid glycoprotein (orosomucoid) was used as a model
Asn-linked glycoprotein substrate to determine the
lysosomal digestive pathway (Fig. 1A). These studies
were done with the rat and human glycoprotein, or
their asialo-derivatives (minus terminal sialic acid
residues), and in vitro with extracts of puri¢ed lyso-
somes [16] or in situ using a perfused rat liver. The
organ system was especially useful since radioactively
labeled asialo-orosomucoid could be metabolically
‘microinjected’ into hepatocyte lysosomes via the
well-characterized asialoglycoprotein receptor that
is unique to these cells [17^20]. Rat K1-acid glycopro-
tein contains 187 amino acids in its polypeptide and
six attached N-linked oligosaccharides [21] (Fig. 1A).
One sugar chain contains a single-branched L-fucose
residue attached K-(1^6) to the core reducing-end
GlcNAc that is joined to Asn. One chain is a trian-
tennary structure, while the other ¢ve are bianten-
nary. A total of 256 H2O molecules are required
for lysosomal hydrolases to catalyze complete disas-
sembly of this glycoprotein into its 187 amino acids
Fig. 1. Lysosomal degradation of Asn-linked glycoproteins.
(A) Structure of rat serum orosomucoid and its complete hy-
drolysis into monosaccharides and amino acids. Rat orosomu-
coid is a 187-amino acid single polypeptide with six biantennary
chains, one triantennary chain, and one fucose that account for
its total 70 monosaccharides. Linkage positions of the sugars
are indicated: O, sialic acid; R, L-D-galactose; E, N-acetyl-L-
D-glucosamine; b, K-D-mannose; a, L-D-mannose; F, K-L-fu-
cose. (B) Bidirectional hydrolysis pathway in lysosomes. Steps
1^5: monosaccharides are cleaved sequentially from the non-re-
ducing end of the oligosaccharides. Steps I^IV: ordered hydrol-
ysis of protein and linkage region. Hydrolysis of the reducing-
end GlcNAc can be catalyzed from either of the two reaction
pathways (Step IV or 3).
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and 70 monosaccharides. This metabolism only re-
quires a set of six or seven glycosidases, a relatively
small group of proteinases (cathepsins A^D, H, L
and S) and a speci¢c glycosylasparaginase for the
protein-to-carbohydrate linkage, which is the topic
of this review (Fig. 1B). In metabolic design, the
overall simultaneous bidirectional disassembly is sim-
ilar to other biochemical pathways, incorporating
usual features, such as ordered reaction steps and a
requirement for relatively few enzymes [15].
2.1. Degradation of oligosaccharide component
The stepwise degradation of the oligosaccharide
component results directly from the substrate specif-
icity of individual lysosomal glycosidases. Most of
them are exo-hydrolases that only recognize a non-
reducing end glycosyl unit as a substrate. This enzy-
matic feature determines that lysosomal K-neurami-
nidase, L-D-galactosidase, N-acetyl-L-D-hexosamini-
dase and K- and L-D-mannosidases perform their
hydrolytic reactions in the same sequential order as
the sugars structurally occur along the bi- or trian-
tennary chains (steps 1^5, Fig. 1B). A variation in
this reaction path is the possibility for separate K-D-
mannosidases to release the 1^3- and 1^6-K-D-man-
nosyl units joined to the L-D-mannosyl branch point
of biantennany chains. A major undigested oligosac-
charide fragment in human K-mannosidosis patients
contains only the K(1C3)-D-mannose branch, which
suggests that a speci¢c K(1C6)-D-mannosidase is
still active in their lysosomes [22]. Such an
K(1C6)-D-mannosidase has been isolated and char-
acterized [23]. This enzyme appears to require the
prior removal of Asn by glycosylasparaginase in or-
der to hydrolyze the 1^6-linked mannose unit [24].
Some Man2GlcNAc2Asn fragments having the 1^6-
mannose were recently found in the liver of an AGU
patient [25]. The fact that this fragment is rarely
observed in AGU tissues is due to the ability of
the major lysosomal K-D-mannosidase to hydrolyze
an K-(1^6)-D-mannose [23]. Sequential L-D-mannosi-
dase and N-acetyl-L-D-glucosaminidase attack would
then yield the ¢nal Asn^GlcNAc fragment.
2.2. Degradation of protein and linkage region
The second part of the bidirectional pathway for
Asn-linked glycoprotein catabolism encompasses di-
gestion of the protein component, the actual linkage-
structure Asn^GlcNAc, and the di-N-acetylchito-
biose core unit (reaction steps I^IV, Fig. 1B). This
portion of degradation is interesting because of the
unique enzymes involved, including glycosylasparagi-
nase. The order for degradation of the protein and
protein-to-carbohydrate components of Asn-linked
glycoproteins is: (I) proteolysis ; (II) removal of any
fucose; (III) hydrolysis of the L-amide of the Asn^
GlcNAc linkage; and (IV) release of the reducing-
end GlcNAc from the di-N-acetylchitobiose core
structure. The latter step can also be catalyzed by
N-acetyl-L-D-glucosaminidase acting from the non-
reducing end of the carbohydrate component (glyco-
sidase 3, Fig. 1B). This occurs when the rate of oli-
gosaccharide digestion is fast enough to expose the
penultimate GlcNAc prior to the glycosylasparagi-
nase reaction. It is noteworthy that extensive proteol-
ysis must occur ¢rst in order for overall digestion of
the linkage region to go to completion.
2.3. Role of glycosylasparaginase
Two major biochemical features of the glycosylas-
paraginase play an important role in de¢ning the
order of the linkage-region reactions. A noteworthy
speci¢city of this amidase is its requirement for both
a free K-amino and K-carboxyl group on the Asn
substrate [26,27]. This enzymic property demands
that there be prior hydrolysis of both peptide bonds
joined to the Asn. Lysosomal cathepsins must there-
fore release the Asn with its associated oligosacchar-
ide (step I, Fig. 1B) before glycosylasparaginase can
react in the pathway.
The second property of glycosylasparaginase reac-
tivity that impinges on the degradation process is its
inhibition by any K-(1^6)-L-fucose that is bound to
the core reducing-end GlcNAc [28,29]. The deoxysu-
gar branch must sterically block the active site of the
enzyme from binding the asparaginyl moiety of the
substrate. This inhibitory feature explains why the
majority of fragments that accumulate in fucosidosis
patients are glycopeptides that retain the Asn residue
[30], and it determines that removal of any fucose is
a prerequisite for glycosylasparaginase to react.
Thus, for each Asn-linked glycoprotein that enters
the lysosomes for turnover, digestion occurs simulta-
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neously from the outer ends of oligosaccharide
chains and along the polypeptide. The common
end-point in catabolism involves the linkage region
where glycosylasparaginase reacts. The relative rates
at which the two parts of the overall degradative
system operate will vary depending on the detailed
chemical structure of a particular glycoprotein. For
example, certain glycosylated asparagines may be in
more protected environments than others, and the
ability of the lysosomal milieu to denature each gly-
coprotein would contribute to the disassembly of
each component.
3. Molecular biology
3.1. cDNA
A full-length cDNA of human glycosylasparagi-
nase was ¢rst cloned in 1990 (Fig. 2) [31]. The
1041-bp open-reading frame1 encoded a protein of
Fig. 2. Human placenta glycosylasparaginase cDNA and AGU mutations. The signal peptide, catalytic nucleophile T206 and exon^in-
tron junctions are in shaded boxes. Two glycosylation sites (N38 and N308) are enclosed by hexagons. Disul¢de bonds C64^C69;
C163^C179; C286^C306; and C317^C345 are shown. The sequence G186^D205 (underlined, italicized) is cleaved from the C-terminus
of the K-subunit in the lysosomes. Amino acid changes caused by nine missense AGU mutations are shown at arrowheads with the
mutated base underlined. There is one nonsense AGU mutation (C64 STOP) and seven AGU-causing insertions or deletions (the lat-
ter two classes are indicated by underlined bases). The mutations are further described in Figs. 3 and 6 and in the text.
1 The protein sequence is numbered from the start methionine
being at position 1 and the nucleotide sequence is numbered from
the start ATG codon with A being at position +1.
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346 amino acids of which the N-terminal 23 residues
form a signal peptide. The signal-free human protein
(residues Ser24^Ile346) has a calculated mass of 34.6
kDa. This polypeptide encompasses both the K- and
L-subunit of glycosylasparaginase, and it immedi-
ately became evident that post-translational cleavage
of a single-chain precursor gives rise to the mature
two-subunit amidase [31,32]. The calculated mass of
the encoded human K-subunit polypeptide (Ser24^
Asp205) is 19.5 kDa and that of the L-subunit
(Thr206^Ile346) is 15.1 kDa. The molecular masses
of the human K and L-subunits observed by SDS-
PAGE are 18 and 23 kDa, respectively [31]. Each
subunit contains one Asn-linked glycosylation se-
quon (K, 38AsnAlaThr; L, 308AsnValThr), and
each of these two Asn residues is glycosylated in
the mature enzyme [33]. These oligosaccharides
would be expected to add a mass of about 2^3
kDa to the enzyme. Four disul¢de bonds occur in
the protein, two in each subunit: Cys64^Cys69;
Cys163^Cys179; Cys286^Cys306; Cys317^Cys345
[48].
3.2. Gene structure and AGU mouse model
The human gene for glycosylasparaginase has been
localized to chromosome region 4q32^q33 [34,35].
This 13-kb gene (Fig. 3) has nine exons with all
exon^intron junctions ¢tting the gt/ag consensus
splicing rule [36]. Exon 1 encodes 5P-untranslated
sequence and the ¢rst 42 amino acids which include
the 23 amino acid signal peptide. Exon 9 codes the
last 33 amino acids and 939 bases of 3P-untranslated
sequence. The major transcriptional start site in the
5P-untranslated region has been experimentally deter-
mined to be at 3298 (relative to the ATG start co-
don) [37]. As observed in genes for many lysosomal
hydrolases, the 5P-promoter region of glycosylaspar-
aginase is typical of housekeeping genes and includes
a GC-rich island. Promoter studies on the 5P-£anking
region of the human glycosylasparaginase gene sug-
gest that Sp1 and Ap-2 binding sites and a possible
inhibitory control region may be important for reg-
ulating its expression [37].
The only other gene structure for glycosylaspara-
ginase besides that in humans was reported for the
mouse [38,39]. The mouse gene spans 11 kb and also
contains nine exons. All of the exon^intron bounda-
ries of the mouse and human genes are equivalently
positioned. Two mRNA transcripts are produced
from both the mouse and human genes. Two exper-
imental mouse models for AGU have now been gen-
erated by targeted disruption of the mouse glycosyl-
asparaginase gene [38,39]. The AGU mice exhibit
very similar pathophysiology as the human patients
[93^96], including widespread hypertrophy of the ly-
sosomes in the central nervous system that leads to a
gradual, progressive motor impairment and ¢nally
Fig. 3. Structures of human glycosylasparaginase gene (AGA) and protein with locations of AGU mutations. The glycosylasparaginase
gene is 13 kb [36] located on chromosome 4q32^q33 [34,35]. Its nine exons are separated by introns whose sizes in kb are shown in
italics. The gene encodes a 346-amino acid single-chain polypeptide [31] that contains a 23-amino acid signal peptide (shaded). Self-
cleavage of the nascent single-chain precursor occurs between residues D205 and T206 (at heavy dotted line in exon 5-encoded region)
to form the active K/L-glycosylasparaginase [38^40]. The mature enzyme loses 20 amino acids from the C-terminus of the K-subunit in
the lysosomes. Relative locations of 21 AGU-causing mutations (a^u) are indicated in both the gene and protein and are described in
Table 1 and the text. Exon and intron sequences can be found in GenBank: U21273^U21281.
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premature death. Older AGU mice display severe
ataxia as seen in dramatic changes in their walking
pattern which seems to coincide with a gross loss of
Purkinje cells [94]. Promising partial correction of
the pathology has been observed in early adenovi-
rus-mediated gene therapy experiments in which
both tail vein and intraventricular injections of the
virus-encoded human glycosylasparaginase were
tested [97]. A normal enzyme activity level returned
to the liver of the AGU animals treated by the tail-
vein injection route. In the brain-treated animals,
some transduced ependymal cells lining the ventricles
appeared also to replace the enzyme in surrounding
areas of neurons. In both types of gene therapy, the
corrective e¡ects lasted for at least a month.
3.3. 3P-Untranslated region
Northern blot analysis indicated two forms of gly-
cosylasparaginase mRNA were in human ¢broblasts
and their sizes were estimated to be 1.4 and 2.2 kb
[37,40]. The genomic structure showed that the 3P-
untranslated region in exon 9 is 939 bp. Three poly-
adenylation signals (AATAAA) are located at bases
1152, 1164 and 1949 of the cDNA. Based on the 1.4
and 2.2 kb sizes of the two mRNAs seen in ¢bro-
blasts and the initiation of transcription at 3298,
both the repeated poly A signals at 1152/1164 and
the one downstream at 1949 appear to be used. This
predicted termination of the mRNAs is substantiated
in the current databases by an approximately equal
number of human glycosylasparaginase ESTs that
extend to these two 3P-sites. It is unlikely that an
intron is in the 3P-untranslated region since a single
cDNA from liver spans this exact genomic sequence.
4. Evolution of glycosylasparaginase
Glycosylasparaginase cDNAs have been deter-
mined for six species: human [31], rat [41], bovine
[41], bacteria (Flavobacterium meningosepticum) [42],
insect (Spodoptera frugiperda) [41] and mouse [43]. In
addition, a plant asparaginase also appears to have
an evolutionary relationship to mammalian glycosyl-
asparaginases [44]. The high homology of the de-
duced amino acid sequences of these forms of the
enzyme was useful for gaining insight into what res-
idues are important for its function. With the excep-
tion of the bacterial and insect enzymes, all cysteines
involved in disul¢des are conserved as well as both
glycosylation sites [41]. The glycosylation site on the
L-subunit is missing from the insect hydrolase, and
one of the two potential disul¢de bonds is absent
from the same insect subunit due to lack of appro-
priate cysteines. However, the most C-terminal po-
tential disul¢de that is important in the overall fold-
ing/structure of the human enzymes is maintained by
insect glycosylasparaginase. There are no disul¢de
Fig. 4. Strand diagram showing three-dimensional structure of
human leukocyte glycosylasparaginase. The enzyme is a mem-
ber of a self-processing N-terminal nucleophile amidohydrolase
family of proteins [2,78,79]. Autoproteolysis forms the two sub-
units (K, green; L, orange) from a single-chain precursor
[31,64,85]. The unique protein fold of this group consists of an
‘KLLK sandwich’ [2], i.e. K-helices layer I, L-sheets II and III,
and K-helices layer IV. The N-terminal nucleophile residue
Thr206 that catalyzes hydrolysis of the Asn-GlcNAc substrate
and the product Asp are shown in the active-site cleft formed
between the two L-sheets. This is a RasMol presentation of ¢le
1APZ [2] from the Brookhaven Protein Data Bank.
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bonds in the bacterial enzyme [45,46]. Essentially all
amino acids that are observed at the active site in the
crystal of the human enzyme (Figs. 4 and 5) are
conserved in all known glycosylasparaginases
[2,45,46]. Another major di¡erence in the bacterial
amidase is the absence of a stretch of about 30 amino
acids from the C-terminus of its K-subunit [45,46].
However, most of this region is cleaved from human
glycosylasparaginase by proteases in the lysosomes
[32], and the important His204^Asp205 unit at the
self-cleavage site between K- and L-subunits is con-
served in the bacterial enzyme. There are several
clusters of highly conserved residues in both the K-
subunit (Ala53^Glu58; Val73^Asp80; Thr86^Asp93)
and L-subunit (Gly233^Gly244; Gly252^Asp261),
whose functions in the protein are not yet under-
stood.
5. Gene defects causing aspartylglycosaminuria
Besides the common mutation that has caused
AGU in Finland [40,65,68], a second minor Finnish
allele [52] and 19 other individual family AGU cases
have been noted throughout the world’s population
(Table 1). Most of the non-Finnish patients are ho-
mozygotes due to having consanguineously related
parents. However, recent discovery of four unrelated
Arab families with the same AGU-causing mutation
[47] suggests that a founder e¡ect may be responsible
for the storage disease in a second region of the
world besides Finland. The molecular basis of causes
and consequences of some of these other mutations
are now understood based on both the AGA gene
structure and crystal structure of the enzyme (Figs.
3 and 6).
5.1. Finnish mutations
The ¢rst AGU mutations to be characterized at
the DNA level were the Finnish G482A and
G488C base changes which resulted in two amino
acid substitutions in the glycosylasparaginase,
Arg161Gln and Cys163Ser (Figs. 2, 3 and 6, muta-
tion n) [40,65,66]. The transition G482A (Arg161Gln)
was shown to be a neutral polymorphism that does
not a¡ect enzyme activity [40]. The G488C transition
(Cys163Ser) will by itself cause loss of glycosylaspar-
aginase [40] and therefore is responsible for the ma-
jor form of Finnish AGU disease. Cys163 forms a
Fig. 5. Mechanism of reaction catalyzed by human glycosylasparaginase. Important active site residues [2] are noted in rectangles with
their important side chains indicated. (The protein sequence is numbered from the start methionine being at position 1.) The catalytic
cycle beginning at the upper left consists of: (a) activation of the hydroxyl of the N-terminal T206 of the L-subunit by its own K-ami-
no group; and nucleophilic attack at the amide carbon of Asn-GlcNAc; (b) stabilization of the tetrahedral intermediate in an oxyan-
ion hole formed by T257 and G258; (c) formation of the L-aspartyl ester through general acid catalysis ; (d) deacylation of the en-
zyme; and (e,f) release of aspartate by this same general base/acid mechanism. Requirement for free K-amino and K-carboxyl groups
on the substrates are due to speci¢c binding of these substrate moieties by D237 and R234, respectively. The initially released 1-amino
N-acetylglucosamine product (c) is non-enzymatically hydrolyzed to ammonia and GlcNAc.
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Table 1
AGU mutations
Mutation (Type) Gene alteration Consequencesa
a (deletion) 37 bp: 99(TTGGCCC)105 or 100(TGGCCCCT)106
or 101(GGCCCTT)107 (exon 1)
Frameshift and premature STOP (23 aa); unstable
mRNA
b (splicing) gt to at (intron 1 splice donor); alternative splicing
6 bp downstream from exon 1; +6 bp in mRNA;
127(+ATGCGG)128
Insertion (+2 aa): 42(AspAla)43 (AH1)b
c (missense) G179A (exon 2) Gly60Asp (AH2)b
d (missense) T183G (exon 2) Cys61Trp (AH2)b
e (nonsense) T192A (exon 2) Cys64(STOP): trace amount of single chain form
f (deletion) 32 bp: 193GA194 or 195GA196 or 197GA198 or
199GA200
Frameshift and premature STOP (45 aa)
g (missense) T214C (exon 2) Ser72Pro (active site)
h (missense) G299A (exon 3) Gly100Glu(AS3)b
i (missense) C302T (exon 3) Ala101Val: (AS3)b single-chain; failed transport to
lysosomes
j (deletion) 31 bp: T335 (exon 3) Frameshift and premature STOP (103 aa)
k (deletion) 35 bp: 367(ACACA)371 (exon 3) Frameshift and premature STOP (118 aa); unstable
mRNA
l (splicing) a to g (intron 3; 7 bp upstream from exon 4); new
favorable ag splice acceptor site; +7 bp in mRNA
Frameshift and premature STOP (146 aa)
m (missense) T404C (exon 4) Phe135Ser (AH4)b
n (missense) G488C (exon 4) Cys163Ser; unable to form Cys163^Cys179 disful¢de;
single-chain; failed transport to lysosomes
o (deletion) 31 bp: G567 (exon 5) Frameshift
p (deletion) 31 bp: T788 or T789 (exon 7) Frameshift and premature STOP (239 aa)
q (insertion) +1 bp: 800(+T)801 (exon 7) Frameshift and premature STOP (295 aa)
r (missense) G904A (exon 8) Gly302Arg (BS5)b
s (missense) T916C (exon 8) Cys306Arg: (BS5)b unable to form Cys286^Cys306
disul¢de
t (splicing) gt to tt (intron 8 splice donor site; exon skipping):
-exon 8
Single-chain; shortened and not transported to
lysosomes
u (rearrangement) 32 kb: deletion starting 1268 bp from the 5P-end of
intron 8 and ending 1830 bp downstream from the
STOP codon; triplication of T19 at the junction
Chimeric mRNA with a novel exon 9; normal level of
mRNA, polyadenylated; single-chain form, rapid
degradation of mutant protein
aSites of mutations (a^r) in the gene and enzyme are noted in Figs. 2, 3 and 6. References are in the text.
bLocation of mutation in secondary structure of glycosylasparaginase (see Fig. 6).
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critical disul¢de bond with Cys179 [48,49] and its
genetic substitution by Ser results in a misfolding
of the protein. The mutant polypeptide remains as
a single-chain form rather than undergoing normal
post-translational cleavage and is degraded rapidly in
the ER. Syva«nen et al. [50] found that 98% of 115
Finnish AGU patients were homozygous for G488C
and G482A, indicating that the major AGUFIN mu-
tation is a result of a founder e¡ect. Seven AGU
patients living in northern Norway were also homo-
zygous for the major Finnish mutation [51] and had
ancestors who immigrated as early as 1700 from the
southeastern parts of Finland, or partly from Russia.
A more precise understanding of the historical origin
of the major Finnish mutation is yet to be deter-
mined [52].
The second AGU-causing allele in heterozygous
combination with the Cys163Ser mutation has been
found in just seven Finnish patients. This minor Fin-
nish allele is a 2-bp deletion in exon 2 of the gene
[52]. One of four GA repeats starting at position 193
of the cDNA is missing in these AGU patients
(Figs. 2 and 3, mutation f) and results in a prem-
ature termination of the translation of glycosylaspar-
aginase mRNA [52]. This region of the glycosylas-
paraginase gene has several repeating or symmetrical
sequences that may contribute to the accumulation
of ¢ve di¡erent AGU mutations clustered in a 50-
base sequence (nucleotides 175^225) within exon 2.
The mRNA level of this -(GA) allele in these com-
pound heterozygous patients was greatly reduced
to 3^11% of the normal glycosylasparaginase mes-
sage. This second mutation contributes to approxi-
mately 1.5% of Finnish AGU cases, with a deduced
carrier frequency of 1:2600. Historically, it appears
to be a relatively new mutation that migrated to Fin-
land from southern and eastern directions according
to the restricted geographical distribution of the pa-
tient families along the southern coast of the coun-
try.
5.2. Splicing mutations
The ¢rst non-Finnish AGU mutation to be char-
acterized at the molecular level was in a 12-year-old
African-American male [53^55,67]. The 3P-terminal
portion of the glycosylasparaginase mRNA from
this patient lacked exon 8 (Table 1, Fig. 3, mutation
t). The exon skipping was due to mutation of gt to tt
at the 5P-splice donor site of intron 8 (Table 1),
which must result in the ag acceptor site of intron
8 dominating that of intron 7. Deletion of exon 8
causes a frameshift and premature termination of
translation. The inactive mutant enzyme was not
processed into two subunits, similar to the conse-
quences of the Finnish AGU major mutation. This
same type of mutation, i.e. loss of exon 8, appears in
one of the two AGU knockout mouse models pro-
duced experimentally by targeted gene disruption
[39]. A second human AGU splicing defect has
caused a seven-base insertion at the junction of exons
3 and 4 in the cDNA of two Japanese siblings
[12,56]. The insertion was due to an a to g transition
at the eighth nucleotide preceding the 3P-end of in-
tron 3, which creates a new consensus splicing ac-
ceptor site ag (Table 1). Exclusive alternative splicing
at the new ag site produced abnormal mRNA with
seven nucleotides of previous intron 3 added to the
5P-end of exon 4. A frameshift results from the seven-
Fig. 6. Secondary structural elements of glycosylasparaginase
and locations of AGU-causing missense mutations. The crystal
structure of human leukocyte glycosylasparaginase [2] is shown
schematically according to the major folding of the protein, i.e.
two layers of L-sheet (II, III), each £anked on one side by a
layer of K-helices (I, IV, respectively). Sheet II consists of eight
strands (AS1^AS4; BS1, BS2 and BS7, BS8) and is £anked by
¢ve K-helices (AH1^AH5); sheet III consists of 4 strands (BS3^
BS6) and is £anked by three K-helices (BH1^BH3). Designation
of these secondary structures are A or B =K- or L-subunit; H
or S =K-helix or L-strand. Locations of AGU missense muta-
tions are indicated by diamonds (mutation b is a splice site mu-
tation resulting in the insertion of two amino acids, see Table
1).
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base insertion that causes translation to be termi-
nated prematurely (Fig. 3, mutation l).
A third splicing mutation occurred in a Tunisian
AGU patient [55] whose cDNA showed a 6-bp in-
sertion at the junction of exons 1 and 2 (Table 1, Fig.
3, mutation b). This insertion can be explained if the
gt splice donor site of intron 1 were mutated to at. If
this g to a transition then leads to splicing from the
next gt in intron 1, the predicted change is: GCA G
gtgcgggtCGCA GAT GCG G gt (Table 1). This
putative mechanism would account for the observed
cDNA sequence of the patient with its insertion of
the hexanucleotide ATGCGG. This in-frame two-co-
don insertion would result in the addition of two
amino acids (AspAla). These two extra amino acids
in the Tunisian patient are in a helix region (AH1) of
the enzyme [2] (Figs. 3 and 6, mutation b), and they
would likely disturb the normal three-dimensional
structure.
5.3. Missense mutations
Two AGU brothers in a British family were
characterized as compound heterozygotes [57]. One
paternally transmitted mutation was a C302T tran-
sition that changed alanine at position 101 to valine
(Figs. 2, 3 and 6, mutation i). Transient expression of
the mutant enzyme in transfected COS-1 cells
showed a similar phenotype to the enzyme formed
in the major Finnish AGU patients; the protein re-
mained a single-chain form without enzymatic activ-
ity, and it was not targeted to lysosomes. Ala101 is
located in a L-strand of the K-subunit (AS3) inside of
the core of the enzyme (Fig. 6, mutation i), and
change to the larger Val should disturb the packing
of the polypeptide. This same paternal C302T muta-
tion occurred in an Italian patient [55]. Missense
mutations in two Canadian compound heterozygous
AGU patients were recently characterized. The ob-
served G299A transition in exon 3 of one patient
causes a Gly100Glu substitution (mutation h, Figs.
2, 3 and 6), and a T404C transition in exon 4 of the
second patient causes a F135S substitution (mutation
m, Figs. 2, 3 and 6). These substitutions lead to ma-
jor changes in the side chain chemistry at these two
positions. Disruption of overall protein folding likely
occurs, since the new amino acids are in important
secondary structures of the K-subunit: AS3 of L-
sheet II and AH4 of K-helices layer I, respectively
(Fig. 6).
A German AGU patient was found to have a
point mutation G179A in exon 2 which changes
Gly60 to Asp (Figs. 2, 3 and 6, mutation c) [55].
This glycine is located in a helix of the K-subunit
(AH2) facing the interior of the enzyme [2] (Fig. 6,
mutation c) and the substitution by aspartic acid
again probably disturbs the packing of the protein.
A Turkish AGU patient had a G904A transition in
exon 8 of the gene [55]. The resulting Gly302Arg
mutation (Figs. 2, 3 and 6, mutation r) occurs in
the core of the enzyme in a L-strand of the L-subunit
(BS5) (Fig. 6, mutation r). A T916C AGU mutation
in exon 8 was found in a caucasian-American patient
to cause Cys306 to be changed to Arg (Figs. 2, 3 and
6, mutation s) [55]. Cys306 forms an important disul-
¢de bond with Cys286. Although the Arg replace-
ment disturbs folding of the protein, experimental
mutation of Cys306 to Ser allows activation to the
two-subunit form of the enzyme [48]. The latter mu-
tant protein, however, was less stable than normal
glycosylasparaginase.
The paternal allele responsible for AGU in a
Dutch heterozygote patient results from a missense
transition T183G in exon 2, which substitutes Trp
for Cys61 (Figs. 2, 3 and 6, mutation d) (Y. Liu
and N.N. Aronson, Jr., unpublished result). This
Cys is the only one in human glycosylasparaginase
that is not involved in a disul¢de bond and its ex-
perimental substitution by Ser does not a¡ect enzyme
activation [48]. The large size and hydrophobic na-
ture of Trp probably disrupts the normal tertiary
structure in this helix region (AH2) of the protein
(Figs. 2, 3 and 6, mutation d). A T214C transition
also in exon 2 was characterized as the cause of
AGU in members of four unrelated Palestinian
Arab families whose origins are in the region of Jer-
usalem (Figs. 2, 3 and 6, mutation g) [47,58]. This
mutation results in substitution of Ser72 by Pro,
and this is the only known disease-causing mutation
that involves an active site residue [58]. The hydroxyl
group of Ser72 is hydrogen bonded to the free K-
amino group of the critical N-terminal nucleophile
Thr206 of the L-subunit. This mutant enzyme form
is transported to lysosomes, but it is not activated
into subunits in the ER. Cleavage into subunits did
occur when the Pro72 substituted protein was over-
BBADIS 61881 10-9-99 Cyaan Magenta Geel Zwart
N.N. Aronson Jr. / Biochimica et Biophysica Acta 1455 (1999) 139^154 149
expressed and secreted into the medium by trans-
fected cells in culture.
5.4. Nonsense mutations
In a Puerto Rican AGU patient with parents who
were ¢rst cousins [61] a mutation T192A changed the
wild-type codon TGT encoding Cys64 to the stop
codon TGA (Figs. 2 and 3, mutation e) [60]. A the-
oretical truncated polypeptide with 63 amino acids
(40 amino acids after signal peptide cleavage) would
be synthesized from the mutant mRNA.
5.5. Insertions and deletions
A single-base insertion of T in exon 7 was ob-
served between positions 800 and 801 in a Spanish^
American patient (Figs. 2 and 3, mutation q) [55]. As
a result of frameshifting and premature termination
of translation, the expected mutant glycosylasparagi-
nase would be shortened by 28 amino acids. The
maternal allele of the British AGU siblings described
above with missense mutation A101V [57] is a 7-bp
deletion from exon 1 (Figs. 2 and 3, mutation a). The
seven consecutive nucleotides could be deleted from
the sequence between 99 and 107 (TTGGCCCTT) in
three possible ways to account for the change ob-
served in the cDNA [57]. This mutation results in a
frameshift that is followed by premature termination
of translation. Another deletion of 5 bp located in
exon 3 was found in the glycosylasparaginase gene of
an American patient [59] (Figs. 2 and 3, mutation k).
The deletion of ACACA (367^371) resulted in sim-
ilar consequences as the 7-bp deletion in the two
British AGU patients, including an apparent de-
creased stability of the mutant mRNA.
An AGU patient of Mauritian origin was found to
have a single-base deletion of either T787 or T788
from exon 7 (Figs. 2 and 3, mutation p) [61]. As a
result of the frameshift and premature translational
termination the mutant enzyme will become short-
ened by 84 amino acids. This truncated polypeptide
contains complete sequence of the K-subunit and half
of that of the L-subunit. When it was expressed in
COS-1 cells the truncated protein remained as a sin-
gle-chain form which suggests that conversion into
two subunits does not take place co-translationally
during folding, but instead requires a de¢nite three
dimensional structure for the cleavage between
Asp205 and Thr206 to occur. Two Dutch AGU al-
leles are deletions of single bases, both of which re-
sult in frameshifting and premature termination of
translation. In one Dutch patient, deletion of a single
T occurred at position 336 in exon 3 (Figs. 2 and 3,
mutation j) [55], and in the second patient, G567 is
deleted from exon 5 (Figs. 2 and 3, mutation o, L.
Liu and N.N. Aronson, Jr., unpublished result).
5.6. Genomic rearrangement
A genomic rearrangement in the glycosylasparagi-
nase gene was characterized in the DNA from the
¢rst AGU case clinically described in the United
States [62]. A 2-kb deletion accompanied by the ad-
dition of T19 repeats was found. The 5P-deletion
breakpoint starts 1258 bp downstream from the 5P-
end of intron 8, while the 3P-breakpoint is located
near the 5P-end of an inverted Alu repeat that is
1830 bp downstream from the normal reading frame
termination codon in exon 9 (Fig. 3, mutation u). A
T19 sequence located at the 5P-end of the inverted
Alu repeat was triplicated and inserted between the
two ends of the deletion breakpoints. After com-
pletely losing the normal exon 9 by this genomic
rearrangement, a new chimeric intron was formed
with a new splice acceptor site located 4326 bp
downstream from the normal termination codon.
The mutant chimeric mRNA contains a new exon
9 which also provides a stop codon and a polyade-
nylation site. This exchange of exon 9 yields a mu-
tant glycosylasparaginase that has a hydrophilic re-
gion at its normal C-terminus replaced by a
hydrophobic group of 16 amino acids. When the
mutant glycosylasparaginase was expressed in COS-
1 cells, an equal amount of mRNA was produced
from the mutant construct compared to the normal
one. This AGU-type polypeptide, however, remained
as a single-chain precursor form and was quickly
degraded within 24 h. One of the knockout mouse
models appears to have one of its two AGU alleles
very similar to this unusual human mutation [39].
5.7. Discussion
A few patterns can be discerned at the molecular
level within this relatively small number of AGU
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mutant alleles described above. Isoniemi et al. [52]
pointed out a mutational ‘hotspot’ in exon 2 of the
gene (Figs. 2 and 3, mutations c^f) that can be ex-
plained by the symmetrical and repeating sequences
in this tract of the DNA (Fig. 2). The only portion of
the glycosylasparaginase gene lacking an AGU mu-
tation is in its middle region between exons 5 and 6
and most of exon 7. Evolutionary pressure to main-
tain these genetic sequences unchanged could be ex-
plained by the critical importance of this part of the
encoded polypeptide for the structure and function
of glycosylasparaginase. Indeed, all putative active-
site residues (Thr206, Thr224, Arg234, Asp237,
Thr257, and Gly258), except Ser72, are in the L-sub-
unit [2,58] and are encoded by these three exons.
Similarly, the self-cleavage site (204HisAspThr206)
which is an essential part of the novel Ntn-amidase
structure and activation mechanism [63,64] is at the
3P-end of exon 5 in this segment of the gene. All of
these critical amino acids near the N-terminus of the
L-subunit are conserved in the sequences of glycosyl-
asparaginases from bacteria to insects to humans
[41]. On the other hand, the C-terminal portion of
the K-subunit is also encoded by exon 5, but this
segment of the enzyme is the most varied in its se-
quence among these species. One could therefore pre-
dict that gene mutations that alter individual amino
acids in this portion of the protein might tend to be
polymorphic and not have detrimental e¡ects on the
enzyme. Indeed, this segment of the human K-sub-
unit is removed when glycosylasparaginase reaches
the lysosomes [32].
6. Glycosylasparaginase as a member of the
N-terminal nucleophile (Ntn) hydrolase family of
proteins
Many of the human AGU mutations can be ex-
plained by their direct e¡ects on the structural biol-
ogy of glycosylasparaginase (Fig. 6). Recently, this
enzyme was noted to be a member of a unique pro-
tein group termed N-terminal nucleophile amidases
(hydrolases) [2,78,79]. Most of these proteins under-
go self-cleavage to create an active hydrolase. The
process has been studied in both the bacterial [64]
and human [85] glycosylasparaginases. The polypep-
tide at the cleavage site appears to adopt a confor-
mation that maintains a substrate pocket into which
the cleaved Asp205 (D151, bacterial) side chain ¢ts
and thereby stabilizes. An active His^Thr^Thr triad
may then be involved: Thr206 is activated upon de-
protonation by His205 that requires interaction with
Thr224. This mechanism closely follows that of the
active enzyme hydrolyzing Asn^GlcNAc. Mature
glycosylasparaginase is folded as an KLLK-sandwich
structure which is characteristic of the Ntn-amidases
(Fig. 4). These domains are schematically depicted in
Fig. 6 as helices I, L-sheet II, L-sheet III and helices
IV, respectively. The majority (c, d, h, i, m, r and s)
of 10 known missense AGU mutations in the protein
coding region occur in either an K-helix or L-sheet
secondary structure motif of the protein. Only one
mutation, Ser72Pro (mutation g), changes an active-
site residue. The major Finnish AGU mutation (mu-
tation n) is detrimental because it destroys the impor-
tant K-subunit Cys163^Cys179 disul¢de that is crit-
ical for folding, which in turn is necessary for self-
cleavage into subunits and activation to occur. Acti-
vation results because the free K-amino group of the
new N-terminal nucleophile, Thr206, is a principal
catalytic residue in the amidase reaction [63]. Thus,
the unique structural biology requirements of glyco-
sylasparaginase as a member of the Ntn-class of en-
zymes largely determines which gene mutations yield
amino acid substitutions that will cause AGU. This
explains why so many of the patient mutations pro-
duce altered proteins that exhibit the same aberrant
phenotype as the major AGUFIN glycosylasparagi-
nase: failure to fold correctly, failure to self-cleave
into the active K/L heterodimer, and failure to be
transported to lysosomes. Another unexplained rep-
etition among the 21 AGU mutations is that four of
the nine codons for Cys residues have been a¡ected.
Because of their importance to the folding and stabil-
ity of glycosylasparaginase [48], substitutions for Cys
are expected to be exceptionally detrimental. Bacte-
rial glycosylasparaginase, however, lacks disul¢des
[98].
7. Future directions
The study of glycosylasparaginase has been excep-
tionally rewarding from many scienti¢c directions.
From a genetic perspective, we have come to under-
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stand the cause of one of approximately 30 genetic
diseases that are almost exclusive to the Finnish her-
itage [69]. Concentration of this genetic disease in a
single human population provides hope that com-
bined current and future scienti¢c knowledge can
be used to decrease the number of AGU births in
Finland and to alleviate the su¡ering of AGU pa-
tients and their families. Medical attempts to accom-
plish this are underway including genetic testing [73]
and counseling [72] and bone marrow transplants
[70,71]. Even more sophisticated therapeutic ap-
proaches, such as enzyme replacement and gene ther-
apy [97], may become possible due to development of
the two knockout-mouse models for AGU [38,39]
and successful correction of the AGU phenotype in
cultured cells by enzyme replacement [74,76,77]. An-
other major scienti¢c discovery made during the
study of glycosylasparaginase is the unique biochem-
ical nature and structural biology of the protein that
is based on its overall folding pattern and on the self-
activation of its nascent single-chain precursor by
autoproteolysis. The newly recognized enzyme family
of which glycosylasparaginase is a member is called
N-terminal nucleophile (Ntn) hydrolyses (amidases)
[78]. This group of enzymes encompasses very impor-
tant catalytic reactions in biology [79,80]: the con-
trolling metabolic steps in biosynthesis of purine nu-
cleotides [81] ; aminosugars [82]; and amino acids (in
plants) [83] and the proteasome whose proteolytic
activity is widely utilized in cellular physiology [84].
Experimental studies on the self-activation of both
human [85] and bacterial [46,64] glycosylasparagi-
nases have already revealed important aspects of
this biochemical process which is now known to be
a unique feature of the N-terminal nucleophile family
of proteins. Many of the other Ntn-hydrolase family
members are complex proteins with multisubunits or
domains, and the results from study of glycosylas-
paraginase and its mutants are likely to become the
model for understanding general features of the acti-
vation process. Most of the Ntn-hydrolases are ami-
dases that cleave the L- or Q-side chain amide of
asparagine or glutamine, or their analogs [79,80].
Glycosylasparaginase has been found also to hydro-
lyze L-amide peptides of Asn [86].
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